With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.873063-62-8,(R)-3-Iodotetrahydrofuran,as a common compound, the synthetic route is as follows.
[0388] N-(3′-Fluoro-5,6′-dimethyl-2,2′-bipyridin-4-yl)-2H-pyrazolo[4,3-b]pyridin-7-amine (43 mg, 0.129 mmol) was dissolved in DMF (2 mL), cooled to 0C and sodium hydride (4.75 mg, 60%), 0.129 mmol) was added. The reaction mixture was stirred for 5 minutes and (R)-3-iodotetrahydrofuran (25.5 mg, 0.129 mmol) was added and further stirred for 5 minutes at room temperature and then heated in a microwave at 65C for 40 minutes. The reaction mixture was then cooled, concentrated in vacuo to give a residue which was combined with MeOH and filtered. The filtrate was purified by preparative HPLC using a Sunfire Prep 5muiotaeta CI 8, 75 X 30 mm column 5 muiotaeta CI 8, 75 X 30 mm column eluting with a gradient of 5-30% acetonitrile (containing 0.035% TFA) in water (containing 0.05% TFA) to give the title compounds as TFA salts: (S)-N-(3′-fluoro-5,6′-dimethyl-2,2′-bipyridin-4-yl)- l-(tetrahydrofuran-3-yl)-lH-pyrazolo[4,3-b]pyridin-7-amine 1H NMR (400 MHz,CHLOROFORM- ) delta ppm 1.27 – 1.42 (m, 1 H) 2.36 – 2.39 (m, 4 H) 2.39 – 2.51 (m, 2 H) 2.55 (s, 3 H) 3.80 – 3.89 (m, 1 H) 4.01 (dd, J=9.85, 7.33 Hz, 1 H) 4.11 – 4.22 (m, 2 H) 7.01 (d, J=3.54 Hz, 1 H) 7.14 (dd, J=8.46, 3.41 Hz, 1 H) 7.31 – 7.44 (m, 2 H) 8.25 (s, 1 H) 8.41 (br. s., 1 H), MS [M+H] found 405.4; and (S)-N-(3*-fluoro-5,6*-dimethyl-2,2,-bipyridin-4-yl)- l-(tetrahydrofuran-3-yl)-lH-pyrazolo[4,3-b]pyridin-7-amine 1H NMR (400 MHz,CHLOROFORM-;/) delta ppm 2.44 (s, 3 H) 2.46 – 2.56 (m, 1 H) 2.57 – 2.70 (m, 4 H) 4.04 (td, J=8.59, 5.56 Hz, 1 H) 4.18 – 4.31 (m, 3 H) 5.22 – 5.33 (m, 1 H) 7.02 (d, J=5.05 Hz, 1 H) 7.13 – 7.23 (m, 2 H) 7.43 (dd, J=10.48, 8.46 Hz, 1 H) 8.13 (d, J=1.26 Hz, 1 H) 8.26 (s, 1 H) 8.41 (d, J=5.05 Hz, 1 H) 8.62 (s, 1 H), MS [M+H] found 405.4.
The synthetic route of 873063-62-8 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; KWOK, Lily; LARSON, John David; SABAT, Mark; WO2011/146287; (2011); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem